Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial
Journal of the European Academy of Dermatology and Venereology · 2026
DOI: 10.1111/jdv.70166 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Tadashi Terui und 15 weiteren Autor:innen. Beteiligte Einrichtung: Nihon University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Psoriasis, Thalidomide, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen Inc., Amgen.
Abstract (Originalsprache)
Background
Palmoplantar pustulosis (PPP) is a difficult‐to‐treat chronic dermatitis with limited treatment options.
Objectives
To report results from a Phase 3 study of apremilast in patients with moderate to severe PPP (NCT05174065).
Methods
In this randomized, placebo‐controlled, double‐blind, confirmatory study, Japanese adults with PPP Area and Severity Index (PPPASI) total score ≥12, PPPASI pustules/vesicles severity score ≥2 and inadequate response to topicals were randomly assigned (1:1) to apremilast or placebo for 16 weeks, followed by an active treatment phase where all patients received apremilast through Week 52. The primary endpoint was a ≥50% reduction in PPPASI total score (PPPASI‐50) at Week 16, evaluated in all randomized patients. Safety outcomes were assessed in all patients who received ≥1 dose of the study drug.
Results
Between March 8, 2022 to April 28, 2023, 176 patients (141 [80%] women, 35 [20%] men) were randomly assigned to apremilast ( n = 88 [50%]) or placebo ( n = 88 [50%]). Mean (SD) PPPASI total score at baseline was 22.1 (8.1) in the apremilast group and 22.0 (8.4) in the placebo group. A significantly greater proportion of patients achieved PPPASI‐50 at Week 16 with apremilast versus placebo (60 of 88 [68%] vs. 31 of 88 [35%]; treatment difference: 32.6% [95% CI: 18.7, 46.5], p < 0.0001). Improvements were maintained through Week 52. The most common adverse events (≥10% of patients) during the double‐blind phase in patients receiving apremilast were diarrhea (placebo: n = 3 [3%]; apremilast: n = 17 [19%]), feces soft (placebo: n = 1 [1%]; apremilast: n = 15 [17%]), headache (placebo: n = 2 [2%]; apremilast: n = 10 [11%]) and nausea (placebo: n = 1 [1%]; apremilast: n = 10 [11%]). There were no events of depression or fatal adverse events.
Conclusions
In this Phase 3 trial, apremilast was effective in Japanese patients with moderate to severe PPP. Adverse events were consistent with the known safety profile of apremilast. ClinicalTrials.gov : NCT05174065.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nihon University School of Medicine, Tokyo, Japan.
- Tokyo Medical University, Tokyo, Japan.
- Seibo International Catholic Hospital, Tokyo, Japan.
- Nagoya City University, Nagoya City, Japan.
- Fukuoka University, Fukuoka, Japan.
- Teikyo University, Tokyo, Japan.
ORCID-Profile: Yukari Okubo, Akimichi Morita, Bruce Strober
Förderung
- Amgen Inc.
- Amgen
Zitieren
APA
Terui, T., Okubo, Y., Kobayashi, S., Morita, A., Imafuku, S., Tada, Y., Abe, M., Strober, B., Gooderham, M., Zhang, W., Shimauchi, J., Yaguchi, M., Kimura, T., Ogawa, R., Amouzadeh, H., & Murakami, M. (2026). Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70166
Vancouver
Terui T, Okubo Y, Kobayashi S, Morita A, Imafuku S, Tada Y, et al. Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70166
BibTeX
@article{Terui2026,
author = {Terui, Tadashi and Okubo, Yukari and Kobayashi, Satomi and Morita, Akimichi and Imafuku, Shinichi and Tada, Yayoi and Abe, Masatoshi and Strober, Bruce and Gooderham, Melinda and Zhang, Wendy and Shimauchi, Junichiro and Yaguchi, Masafumi and Kimura, Takeshi and Ogawa, Ryuichi and Amouzadeh, Hamid and Murakami, Masamoto},
title = {Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2026},
doi = {10.1111/jdv.70166}
}
EUVIMED